{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:26:33Z","timestamp":1792689993081,"version":"4.5.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32071462"],"award-info":[{"award-number":["32071462"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2021YFH0167"],"award-info":[{"award-number":["2021YFH0167"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Metabolic associated fatty liver disease (MAFLD) affects nearly a quarter of the world\u2019s population. Our study aimed to characterize the gut microbiome and overall changes in the fecal and serum metabolomes in MAFLD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Thirty-two patients diagnosed with MAFLD and 30 healthy individuals (control group, CG) were included in this study, the basic clinical characteristics and laboratory test results including routine biochemistry, etc. were recorded for all, and their serum and fecal samples were collected. A portion of the fecal samples was subjected to 16S rDNA sequencing, and the other portion of the fecal samples and serum samples were subjected to non-targeted metabolomic detection based on liquid chromatography-mass spectrometry (LC\u2013MS). Statistical analysis of clinical data was performed using SPSS software package version 25.0 (SPSS Inc., Chicago, IL, United States). The analysis of 16S rDNA sequencing results was mainly performed by R software (V. 2.15.3), and the metabolomics data analysis was mainly performed by CD 3.1 software. Two-tailed <jats:italic>p<\/jats:italic> value\u2009&amp;lt;\u20090.05 was considered statistically significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 16S sequencing data suggested that the species richness and diversity of MAFLD patients were reduced compared with controls. At the phylum level, the relative abundance of <jats:italic>Bacteroidota<\/jats:italic>, <jats:italic>Pseudomonadota<\/jats:italic>, and <jats:italic>Fusobacteriota<\/jats:italic> increased and <jats:italic>Bacillota<\/jats:italic> decreased in MAFLD patients. At the genus level, the relative abundances of <jats:italic>Prevotella<\/jats:italic>, <jats:italic>Bacteroides<\/jats:italic>, <jats:italic>Escherichia-Shigella<\/jats:italic>, etc. increased. 2,770 metabolites were detected in stool samples and 1,245 metabolites were detected in serum samples. The proportion of differential lipid metabolites in serum (49%) was higher than that in feces (21%). There were 22 differential metabolites shared in feces and serum. And the association analysis indicated that LPC 18:0 was positively correlated with <jats:italic>Christensenellaceae_R-7_group<\/jats:italic>, <jats:italic>Oscillospiraceae_UCG-002<\/jats:italic>; neohesperidin was also positively correlated with <jats:italic>Peptoniphilus<\/jats:italic>, <jats:italic>Phycicoccus<\/jats:italic>, and <jats:italic>Stomatobaculum<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Microbial sequencing data suggested decreased species richness and diversity and altered \u03b2-diversity in feces. Metabolomic analysis identified overall changes in fecal and serum metabolites dominated by lipid molecules. And the association analysis with gut microbes provided potentially pivotal gut microbiota-metabolite combinations in MAFLD patients, which might provide new clues for further research on the disease mechanism and the development of new diagnostic markers and treatments.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmicb.2022.969757","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T07:53:23Z","timestamp":1661154803000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Integrative analysis of gut microbiota and fecal metabolites in metabolic associated fatty liver disease patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Lidan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenling","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenmei","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1128\/mSphere.01202-20","article-title":"Primer, pipelines, parameters: issues in 16S rRNA gene sequencing","volume":"6","author":"Abellan-Schneyder","year":"2021","journal-title":"mSphere"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/liv.14453","article-title":"Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"40","author":"Adams","year":"2020","journal-title":"Liver Int."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41592-021-01197-1","article-title":"Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices","volume":"18","author":"Alseekh","year":"2021","journal-title":"Nat. Methods"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cphy.c170012","article-title":"Triglyceride metabolism in the liver","volume":"8","author":"Alves-Bezerra","year":"2017","journal-title":"Compr. Physiol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/ismej.2012.8","article-title":"Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms","volume":"6","author":"Caporaso","year":"2012","journal-title":"ISME J."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature12820","article-title":"Diet rapidly and reproducibly alters the human gut microbiome","volume":"505","author":"David","year":"2014","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"G900","DOI":"10.1152\/ajpgi.00265.2013","article-title":"Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids","volume":"305","author":"den Besten","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1530\/JOE-20-0018","article-title":"SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD","volume":"245","author":"Deng","year":"2020","journal-title":"J. Endocrinol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1126\/science.1110591","article-title":"Diversity of the human intestinal microbial flora","volume":"308","author":"Eckburg","year":"2005","journal-title":"Science"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"","journal-title":"J. Hepatol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"","journal-title":"Hepatol. Int."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1751-2980.2010.00476.x","article-title":"Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese journal of Hepatology 2010; 18:163-166)","volume":"12","author":"Fan","year":"2011","journal-title":"J. Dig. Dis."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.3389\/fphar.2018.01354","article-title":"Gut microbiota, short-chain fatty acids, and herbal medicines","volume":"9","author":"Feng","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/sjg.sjg_357_21","article-title":"The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"28","author":"Fouad","year":"2022","journal-title":"Saudi J. Gastroenterol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/pathogens3010014","article-title":"Metabolism of cholesterol and bile acids by the gut microbiota","volume":"3","author":"G\u00e9rard","year":"2013","journal-title":"Pathogens"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","article-title":"Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis","volume":"15","author":"Jia","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD","volume":"13","author":"Leung","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1039\/D0FO02736G","article-title":"Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K\/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD","volume":"12","author":"Li","year":"","journal-title":"Food Funct."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12944-021-01440-w","article-title":"Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and meta-analysis","volume":"20","author":"Li","year":"","journal-title":"Lipids Health Dis."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"603654","DOI":"10.3389\/fped.2020.603654","article-title":"New perspectives on genetic prediction for pediatric metabolic associated fatty liver disease","volume":"8","author":"Lin","year":"2020","journal-title":"Front. Pediatr."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"972","DOI":"10.14218\/JCTH.2021.00201","article-title":"Epidemiology and clinical outcomes of metabolic (dysfunction)-associated fatty liver disease","volume":"9","author":"Lin","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"12053","DOI":"10.1096\/fj.201903102RR","article-title":"Neohesperidin attenuates obesity by altering the composition of the gut microbiota in high-fat diet-fed mice","volume":"34","author":"Lu","year":"2020","journal-title":"FASEB J."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3390\/nu11071578","article-title":"The potential use of metabolic cofactors in treatment of NAFLD","volume":"11","author":"Mardinoglu","year":"2019","journal-title":"Nutrients"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3945\/an.116.013151","article-title":"Nonalcoholic fatty liver disease, the gut microbiome, and diet","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Adv. Nutr."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/19490976.2015.1134082","article-title":"Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism","volume":"7","author":"Morrison","year":"2016","journal-title":"Gut Microbes"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"723479","DOI":"10.3389\/fmicb.2021.723479","article-title":"Multivariate analysis in microbiome description: correlation of human gut protein degraders, metabolites, and predicted metabolic functions","volume":"12","author":"Raimondi","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jnim.2018.12.004","article-title":"Bioflavonoid hesperidin possesses the anti-hyperglycemic and hypolipidemic property in STZ induced diabetic myocardial infarction (DMI) in male Wister rats","volume":"15","author":"Rekha","year":"2019","journal-title":"J. Nutr. Intermed. Metabol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MOG.0000000000000057","article-title":"Bile acids and the gut microbiome","volume":"30","author":"Ridlon","year":"2014","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11306-018-1369-1","article-title":"Group-wise ANOVA simultaneous component analysis for designed omics experiments. Metabolomics: official journal of the Metabolomic","volume":"14","author":"Saccenti","year":"2018","journal-title":"Society"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1111\/j.1572-0241.2002.05925.x","article-title":"Xanthine oxidoreductase activity in human liver disease","volume":"97","author":"Stirpe","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3389\/fgene.2019.00454","article-title":"Multi-Omic analysis of the microbiome and metabolome in healthy subjects reveals microbiome-dependent relationships between diet and metabolites","volume":"10","author":"Tang","year":"2019","journal-title":"Front. Genet."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association Between fibrosis stage and outcomes of patients With nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.arcmed.2021.04.005","article-title":"Hepatic accumulation of hypoxanthine: a link between Hyperuricemia and nonalcoholic fatty liver disease","volume":"52","author":"Toledo-Ibelles","year":"2021","journal-title":"Arch. Med. Res."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/biom12010056","article-title":"Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives","volume":"12","author":"Vallianou","year":"2021","journal-title":"Biomol. Ther."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"32002","DOI":"10.1038\/srep32002","article-title":"Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41387-020-00130-3","article-title":"Neohesperidin enhances PGC-1\u03b1-mediated mitochondrial biogenesis and alleviates hepatic steatosis in high fat diet fed mice","volume":"10","author":"Wang","year":"2020","journal-title":"Nutr. Diabetes"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cmet.2019.08.018","article-title":"Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae","volume":"30","author":"Yuan","year":"2019","journal-title":"Cell Metab."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"fnz153","DOI":"10.1093\/femsle\/fnz153","article-title":"Dietary butyrate suppresses inflammation through modulating gut microbiota in high-fat diet-fed mice","volume":"366","author":"Zhai","year":"2019","journal-title":"FEMS Microbiol. Lett."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3748\/wjg.v23.i1.60","article-title":"Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier","volume":"23","author":"Zhou","year":"2017","journal-title":"World J. Gastroenterol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.969757\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T07:53:26Z","timestamp":1661154806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.969757\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":45,"alternative-id":["10.3389\/fmicb.2022.969757"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2022.969757","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"article-number":"969757"}}